Olema Pharmaceuticals (OLMA) Price & Analysis

Compare

742 Followers

OLMA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$2.86 - $13.93

Previous CloseN/A

Volume1.27M

Average Volume (3M)890.90K

Market Cap

$549.07M

Enterprise Value-$70.36M

Total Cash (Recent Filing)$361.91M

Total Debt (Recent Filing)$1.75M

Price to Earnings (P/E)―

Beta1.78

Next Earnings

Nov 11, 2025

EPS Estimate

-0.47

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.51

Shares Outstanding68,634,330

10 Day Avg. Volume1,771,348

30 Day Avg. Volume890,897

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.13

Enterprise Value/Revenue-193.29

Enterprise Value/Gross Profit1.72K

Enterprise Value/Ebitda0.45

Forecast

1Y Price Target

$24.50

Price Target Upside210.52% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

Bulls Say, Bears Say

Bulls Say

Market PotentialOlema currently estimates the 1L market in combination with a CDK4/6i at over ~$10B, representing one of the most coveted commercial settings in oncology.

Partnerships And CollaborationsOlema announced a clinical trial agreement with Pfizer to explore palazestrant combined with atirmociclib for the treatment of metastatic breast cancer.

Trial DevelopmentsNovartis is collaborating on the OPERA-02 trial by providing a free drug supply of ribociclib, valued at $275 million, which shows strong support and confidence in the study.

Bears Say

Competitive ConcernsA question remains about the future of oral SERD + CDK4/6i combinations if Pfizer's atirmociclib + letrozole combination is successful in the corresponding Phase 3 trial.

Regulatory ChallengesA pivotal trial involving an oral SERD with atirmociclib might conflict with the FDA's view on novel-on-novel combinations in advanced/metastatic ER+ breast cancer.

Olema Pharmaceuticals News

Oppenheimer says Olema collaboration with Pfizer could lead to bidding war

Oppenheimer analyst Matthew Biegler says the firm had a chance to speak with Olema Oncology (OLMA) management after...

15d ago

NVS

PFE

Olema Oncology announces new trial agreement with Pfizer

Olema Pharmaceuticals (OLMA) announced a new clinical trial collaboration and supply agreement with Pfizer (PFE) in metastatic breast...

16d ago

PFE

OLMA

Buy Recommendation for Olema Pharmaceuticals Driven by Strategic Collaborations and Promising Clinical Developments

Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on Olema Pharmaceuticals. The associated price target...

16d ago

OLMA

Strategic Collaboration with Pfizer Boosts Olema Pharmaceuticals’ Prospects in ER+ Breast Cancer Treatment

Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on Olema Pharmaceuticals and keeping the price target...

16d ago

OLMA

Olema Pharmaceuticals Partners with Pfizer for New Trial

Olema Pharmaceuticals ( ($OLMA) ) has provided an update. On September 2, 2025, Olema Pharmaceuticals announced a new...

16d ago

OLMA

Olema Pharmaceuticals: Strategic Advancements and Market Potential in Oncology Drive Buy Rating

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on OLMA stock, giving a Buy rating...

1M ago

OLMA

Promising Efficacy and Strategic Partnerships Drive Buy Rating for Olema Pharmaceuticals

Olema Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from...

1M ago

OLMA

Citi ups Olema target, adds ‘upside catalyst watch’

Citi raised the firm’s price target on Olema Oncology (OLMA) to $21 from $20 and keeps a Buy...

1M ago

OLMA

Olema Pharmaceuticals Advances Breast Cancer Therapies

Olema Pharmaceuticals, Inc. ( ($OLMA) ) has released its Q2 earnings. Here is a breakdown of the information...

1M ago

OLMA

Olema Pharmaceuticals: Promising Advancements in ER+ Breast Cancer Treatment and Strategic Positioning Justify Buy Rating

Olema Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Sam Slutsky from...

1M ago

OLMA

Olema Pharmaceuticals Reports Q2 2025 Financial Results

Olema Pharmaceuticals ( ($OLMA) ) just unveiled an announcement. On August 11, 2025, Olema Pharmaceuticals reported its second...

1M ago

OLMA

Olema Oncology reports Q2 EPS (51c), consensus (44c)

Cash, cash equivalents, and marketable securities of $361.9M as of June 30. “Having achieved regulatory alignment on the...

1M ago

OLMA

OLMA Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Olema Pharmaceuticals, Inc. (OLMA) is scheduled to report 2nd quarter earnings on 08/12/2025. Regarding Q2 estimates, Wall Street...

1M ago

OLMA

Olema Pharmaceuticals Holds Annual Stockholders Meeting

Olema Pharmaceuticals ( ($OLMA) ) has issued an update. On June 10, 2025, Olema Pharmaceuticals held its annual...

3M ago

OLMA

OLMA FAQ

What was Olema Pharmaceuticals’s price range in the past 12 months?

Olema Pharmaceuticals lowest stock price was $2.86 and its highest was $13.93 in the past 12 months.

What is Olema Pharmaceuticals’s market cap?

Olema Pharmaceuticals’s market cap is $549.07M.

When is Olema Pharmaceuticals’s upcoming earnings report date?

Olema Pharmaceuticals’s upcoming earnings report date is Nov 11, 2025 which is in 54 days.

How were Olema Pharmaceuticals’s earnings last quarter?

Olema Pharmaceuticals released its earnings results on Aug 11, 2025. The company reported -$0.51 earnings per share for the quarter, missing the consensus estimate of -$0.376 by -$0.134.

Is Olema Pharmaceuticals overvalued?

According to Wall Street analysts Olema Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Olema Pharmaceuticals pay dividends?

Olema Pharmaceuticals does not currently pay dividends.

What is Olema Pharmaceuticals’s EPS estimate?

Olema Pharmaceuticals’s EPS estimate is -0.47.

How many shares outstanding does Olema Pharmaceuticals have?

Olema Pharmaceuticals has 68,634,330 shares outstanding.

What happened to Olema Pharmaceuticals’s price movement after its last earnings report?

Olema Pharmaceuticals reported an EPS of -$0.51 in its last earnings report, missing expectations of -$0.376. Following the earnings report the stock price went up 16.193%.

Which hedge fund is a major shareholder of Olema Pharmaceuticals?

Currently, no hedge funds are holding shares in OLMA

Olema Pharmaceuticals Stock Smart Score

Outperform

Fundamentals

Return on Equity

-49.72%

Trailing 12-Months

Asset Growth

50.07%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Olema Pharmaceuticals

Olema Pharmaceuticals, Inc. (OLMA) is a clinical-stage biopharmaceutical company focused on developing targeted therapies for women's cancers. The company's primary focus is on the discovery and development of therapies for hormone receptor-positive breast cancer. Olema's lead product candidate, OP-1250, is designed to be a potential best-in-class complete estrogen receptor antagonist (CERAN) that inhibits estrogen receptor-positive (ER+) cancer growth.

Olema Pharmaceuticals (OLMA) Earnings & Revenues

Historic Earnings Reports

OLMA Stock 12 Month Forecast

Average Price Target

$24.50

▲(210.52% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","29":"$29","8.75":"$8.75","15.5":"$15.5","22.25":"$22.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$28.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$24.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$21.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,8.75,15.5,22.25,29],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.47,8.126153846153846,9.782307692307693,11.438461538461539,13.094615384615384,14.75076923076923,16.40692307692308,18.063076923076924,19.71923076923077,21.375384615384615,23.03153846153846,24.68769230769231,26.343846153846155,{"y":28,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.47,7.856923076923077,9.243846153846153,10.63076923076923,12.017692307692307,13.404615384615385,14.791538461538462,16.178461538461537,17.565384615384616,18.95230769230769,20.33923076923077,21.726153846153846,23.11307692307692,{"y":24.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.47,7.587692307692308,8.705384615384615,9.823076923076922,10.94076923076923,12.05846153846154,13.176153846153845,14.293846153846154,15.411538461538463,16.529230769230768,17.646923076923077,18.764615384615386,19.88230769230769,{"y":21,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16.46,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.8,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.3,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.62,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.21,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.83,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.11,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.37,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.34,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.29,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.38,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.33,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.47,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >